OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance
Yuqi Yang1, Zhuo-Xun Wu1, Jing-Quan Wang1
1Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, United States.
Abstract:
OTS964 is a potent T-LAK cell-originated protein kinase (TOPK) inhibitor. Herein, we investigated the interaction of OTS964 and multidrug resistance (MDR)-associated ATP-binding cassette sub-family G member 2 (ABCG2). The cell viability assay indicated that the effect of OTS964 is limited in cancer drug-resistant and transfected cells overexpressing ABCG2. We found that the known ABCG2 transporter inhibitor has the ability to sensitize ABCG2-overexpressing cells to OTS964. In mechanism-based studies, OTS964 shows inhibitory effect on the efflux function mediated by ABCG2, and in turn, affects the pharmacokinetic profile of other ABCG2 substrate-drugs. Furthermore, OTS964 upregulates ABCG2 protein expression, resulting in enhanced resistance to ABCG2 substrate-drugs. The ATPase assay demonstrated that OTS964 stimulates ATPase activity of ABCG2 in a concentration-dependent manner. The computational molecular docking analysis combined with results from ATPase assay suggested that OTS964 interacts with drug-binding pocket of ABCG2 and has substrate-like behaviors. Thus, OTS964 is an MDR-susceptible agent due to its interactions with ABCG2, and overexpression of ABCG2 transporter may attenuate its therapeutic effect in cancer cells.
Insights
OTS964, a TOPK inhibitor, interacts with ABCG2, a multidrug resistance transporter. This interaction limits OTS964
Area of Science:
- Pharmacology
- Molecular Biology
- Cancer Research
Background:
- Multidrug resistance (MDR) in cancer is a significant challenge, often mediated by efflux pumps like ABCG2.
- OTS964 is a potent inhibitor of T-LAK cell-originated protein kinase (TOPK).
Purpose of the Study:
- To investigate the interaction between OTS964 and the ABCG2 transporter.
- To understand how ABCG2 affects the efficacy of OTS964 in cancer cells.
Main Methods:
- Cell viability assays in cells overexpressing ABCG2.
- Mechanism-based studies on ABCG2 efflux function and ATPase activity.
- Computational molecular docking analysis.
Main Results:
- OTS964 efficacy is reduced in cells overexpressing ABCG2.
- OTS964 inhibits ABCG2 efflux and stimulates its ATPase activity.
- OTS964 interacts with the ABCG2 drug-binding pocket, exhibiting substrate-like behavior.
- OTS964 upregulates ABCG2 expression, increasing resistance to other ABCG2 substrates.
Conclusions:
- OTS964 is susceptible to multidrug resistance due to its interaction with ABCG2.
- ABCG2 overexpression can attenuate the therapeutic effect of OTS964 in cancer treatment.
- Understanding this interaction is crucial for optimizing cancer therapy involving OTS964.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Related Concept Videos
Treatment Resistant Cancers
ABC Transporters: Exporter
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
ABC Transporters: Importer
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
Targeted Cancer Therapies
There are several types of targeted therapies against...
